Keywords: Gilead Sciences, Ranexa, Angina, Diabetes patients, Ph IV

Gilead's Ranexa reduces angina frequency in patients with type 2 diabetes

Article | 11 March 2013

Print This

US biotech firm Gilead Sciences (Nasdaq: GILD) has announced data from the Phase IV TERISA (Type 2 Diabetes Evaluation of Ranolazine ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in